Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Endocal-Max is a comprehensive nutritional supplement developed and marketed by Precia Pharma, primarily indicated for the management of bone-related conditions such as osteoporosis, osteopenia, and calcium deficiency. The formulation is an advanced version of the company's calcium line, combining **calcium orotate** with synergistic vitamins and minerals. Calcium orotate is a highly bioavailable calcium salt of orotic acid that facilitates the transport of calcium across cell membranes directly into tissues like bone and cartilage. To optimize calcium utilization, Endocal-Max includes **cholecalciferol (Vitamin D3)**, which promotes intestinal calcium absorption, and **menaquinone-7 (Vitamin K2-7)**, which activates vitamin K-dependent proteins like osteocalcin to ensure calcium is deposited in the bone matrix rather than the vasculature. The product also contains **methylcobalamin** for nerve health and essential minerals including **zinc**, **magnesium**, and **boron**, which serve as structural components and enzymatic cofactors in bone metabolism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Endocal-Max.